Location:2009 Annual Report
1a. Objectives (from AD-416)
To assess the pathogenicity and infectivity of influenza vaccine reassortants and their respective parental wild type viruses for chickens. This includes: 1) determining in vivo pathotype of wild type and reassortant vaccine candidate strains in chickens, and 2) assess in vivo infectivity and pathogenicity in chickens using simulated natural route of exposure (intranasal).
1b. Approach (from AD-416)
The challenge studies will be conducted in BSL-3 Enhanced facilities. Four vaccine candidates will be tested per year using the below study design: 1) conducting in vivo pathotype of virus strains by intravenous testing in chickens using intravenous pathogenicity index, and 2) conducting in vivo infectivity and pathogenicity testing by intranasal inoculation of chickens and determining the ability for the virus to grow as evident by virus shedding for oropharynx and cloaca, and ability to cause disease by assessing clinical features, serological reaction and histopathological changes to various organs.
3. Progress Report
The project is related to objective 2 of the in-house project: Development of improved Newcastle disease control strategies addressing issues important to virus transmission, vaccines and vaccination, diagnostics, or international trade. Develop models to show vaccine is a viable method of controlling avian paramyxovirus outbreaks. As part of US pandemic plan, CDC developed low pathogenic strains for potential vaccines through use of reverse genetics. This agreement tests such strains for possible virulence as a regulatory requirement and conducts research in poultry with such viruses. During 2009, ARS submitted an agreement to CDC for approval and funding. The agreement is pending at CDC. Monitoring: The Principal Investigator had regular email and telephone conversations with the cooperator on progress towards approval of agreement and fund transfer.